Antiviral immunity is initiated in virus-infected cells by sensors of the innate immune system that detect viral nucleic acids 1 . These sensors must detect viral RNA or DNA among a vast excess of cellular RNA and DNA, which presents the challenge of discriminating self from non-self and the risk of inappropriate immune responses to self nucleic acids. The specificity of these innate antiviral sensors is achieved mainly by the detection of unique structural features that distinguish viral nucleic acids. For example, the RNA helicase RIG-I binds to 5′-triphosphate RNA that is present in the genomes of many classes of RNA viruses but is scarce in host cells 2 . Similarly, the RNA helicase Mda5 is activated by long, double-stranded viral RNA that is not routinely formed in host cells 3 . For the sensing of intracellular DNA by the interferon-stimulatory DNA (ISD) pathway, the mechanisms for the discrimination of self from non-self are less clear, because the known sensors of DNA are activated in a sequenceindependent fashion by nearly any double-stranded DNA 4-6 . Indeed, published crystal structures of several intracellular DNA receptors have revealed that most molecular contacts with immunostimulatory DNA are made with the sugar-phosphate backbone and not with specific bases 7-9 .
often initiated by endonucleolytic cleavage of the RNA, followed by degradation of the two resulting products by distinct enzyme complexes 13 . The exonuclease XRN1 metabolizes RNA in the 5′-to-3′ direction, and the RNA exosome degrades RNA in the 3′-to-5′ direction 13 . The RNA exosome is a multiprotein complex composed of several core factors associated with key accessory proteins that determine its subcellular localization and RNA substrate specificity 14 . The RNA exosome responsible for the turnover of RNA in the cytoplasm of human cells is formed by the RNA helicase SKIV2L together with additional subunits that are well characterized in yeast (SKI3 and SKI8) 15 but remain poorly defined in humans. A published study has identified SKIV2L as a gene potentially linked to susceptibility to the autoimmune disorder systemic lupus erythematosus in humans 16 . We established stable, robust knockdown of SKIV2L or XRN1 in primary mouse bone marrow-derived macrophages (BMDMs) through the use of lentivirus-delivered short hairpin RNA (shRNA) and confirmed depletion of these proteins by immunoblot analysis (Fig. 1a) . We stimulated these cells by transfection of a pure triphosphate RNA ligand for RIG-I 17 and measured transcription of mRNA encoding interferon-β (IFN-β) as the chief and most direct cytokine 'readout' of activation of the RLR pathway. We found that cells depleted of SKIV2L exhibited a substantially greater IFN-β response to RIG-I ligand than did cells treated with control shRNA with a scrambled sequence, and that knockdown of XRN1 had no effect on the production of IFN-β ( Fig. 1b) . Cells depleted of SKIV2L also had an enhanced IFN-β response to transfection of the synthetic RNA duplex poly(I:C), which activates both RIG-I and Mda5 (Fig. 1c) . After stimulation with RIG-I ligand, the abundance of mRNA encoding IFN-α4, the inflammatory chemokine CXCL10 and interleukin 6 (IL-6) was similarly enhanced in cells depleted of SKIV2L but not in those depleted of XRN-1 ( Fig. 1d-f) , which demonstrated broad enhancement of the RLRactivated antiviral response conferred by knockdown of SKIV2L.
The enhancement of the antiviral response in cells depleted of SKIV2L could have been a result of increased mRNA stability conferred by loss of a key participant in the regulation of mRNA turnover. To control for the specificity of depletion of SKIV2L, we stimulated cells with two non-nucleic acid ligands that each potently induce the type I interferon response. The chemotherapeutic agent DMXAA (5,6-dimethylxanthenone-4-acetic acid) binds to and activates the adaptor STING 18, 19 , and lipopolysaccharide triggers IFN-β production through Toll-like receptor 4 and the adaptor TRIF 20 . We found that cells depleted of SKIV2L did not exhibit enhanced responses to these non-RNA ligands (Fig. 1g,h) .
These data suggested that SKIV2L was a specific negative regulator of the RNA-activated RLR response.
The UPR triggers interferons in cells depleted of SKIV2L
We considered the potential existence of endogenous immunostimulatory RNAs that, after they accumulate in cells, might trigger the RLRs. We hypothesized that the UPR might provide a source of such RNAs. The UPR is a stress response that is activated when the burden of newly synthesized polypeptides in the endoplasmic reticulum (ER) exceeds its protein-folding capacity 21 . Activation of the UPR induces the expression of genes that encode ER protein chaperones, ER membrane-biosynthetic enzymes and the ER-associated proteindegradation machinery and thus restores homeostasis by increasing the size and functional capacity of the ER 22 . One key component of the UPR is the ER-resident transmembrane kinase and endoribonuclease IRE-1 (refs. 23, 24) . The ER-luminal domain of IRE-1 is activated directly by misfolded proteins 25, 26 , which leads to the activation of its cytosolic RNA-endonuclease domain. The main role of IRE-1 in induction of the UPR is to catalyze the removal of a small intron from mRNA encoding the transcription factor XBP1 by precisely cleaving this mRNA at each end of the intron 27, 28 . The resulting exons are then spliced by tRNA ligase 29 ; this newly spliced mRNA encodes functional XBP1 protein, which migrates to the nucleus and induces the expression of dozens of UPR-inducible genes 21 . In addition to its role in splicing XBP1 mRNA, IRE-1 in metazoan organisms also mediates the destructive cleavage of many mRNAs localized near the ER 30, 31 . This regulated IRE-1-dependent RNA decay transiently reduces the burden of newly synthesized proteins entering the ER and protects it from further proteotoxic stress 30 . Endonuclease cleavage by IRE-1 npg generates RNAs with a 3′ cyclic phosphate moiety, and these RNAs are efficiently cleared by the SKI2 RNA exosome 30 . Notably, RNAs containing 3′ cyclic phosphates are able to activate RLRs 32, 33 . Moreover, a published study has found that activation of the UPR by cholera toxin triggers an IRE-1-dependent, RIG-I-mediated inflammatory response 34 . On the basis of such findings, we reasoned that activation of the UPR in cells depleted of SKIV2L might result in the accumulation of endogenous RNA-cleavage products generated by IRE-1 that could elicit an ectopic type I interferon response. We knocked down SKIV2L or XRN1 in immortalized mouse embryonic fibroblasts (MEFs) and then stimulated these cells with thapsigargin, a chemical inhibitor of the sarcoplasmic reticulumendoplasmic reticulum calcium ATPase SERCA, which depletes the ER of its calcium stores and triggers a potent UPR. Upon induction of the UPR, we found that cells depleted of SKIV2L activated substantial production of IFN-β that we did not observe in either cells depleted of XRN1 or cells transduced with control shRNA with a scrambled sequence ( Fig. 2a) . We observed similar induction of the expression of IFN-β mRNA in primary BMDMs depleted of SKIV2L and treated with thapsigargin, but again not in macrophages transduced with the control shRNA or macrophages depleted of XRN1 ( Fig. 2b) . To extend those findings, we treated BMDMs with tunicamycin, a nucleoside antibiotic that inhibits N-linked glycosylation and induces npg the UPR by causing the accumulation of unglycosylated proteins in the ER 21 . We treated macrophages with thapsigargin or tunicamycin and monitored the kinetics of activation of the UPR by tracking the IRE-1-dependent splicing of XBP1 mRNA 35 . We found that thapsigargin-induced splicing of XBP1 mRNA was nearly complete at 2 h after treatment and returned to baseline by 24 h (Fig. 2c) . In contrast, tunicamycin-induced splicing of XBP1 mRNA occurred with delayed kinetics, commencing at 6 h and continuing through 24 h (Fig. 2c) . Notably, both thapsigargin and tunicamycin activated IFN-β production in cells depleted of SKIV2L with kinetics that precisely mirrored the activation of IRE-1 (Fig. 2d,e ). Thus, two mechanistically distinct activators of the UPR triggered a substantial antiviral response in cells depleted of SKIV2L. We next investigated whether the enhanced UPR-induced interferon response in cells depleted of SKIV2L required IRE-1 activity. To do this, we used the genome-editing approach based on clustered regularly interspaced short palindromic repeats (CRISPR) and the endonuclease Cas9 (refs. 36, 37) to target the endogenous gene that encodes IRE-1α (Ern1). We developed a construct similar to one described in a published report 38 that enables coexpression of a guide RNA and Cas9 from a single lentiviral vector. We targeted coding exons of Ern1 in immortalized MEFs with two different guide RNAs and found nearly complete modification of the target sites in these cells several days after selection for transduced cells (Supplementary Fig. 1) . The targeted cells had reduced expression of IRE-1α protein and had severely compromised UPR-induced splicing of XBP1 mRNA compared with that of control cells transduced to express Cas9 alone ( Fig. 3a,b) , which demonstrated extensive loss of IRE-1α function in the targeted cells. We next knocked down SKIV2L in the control cells transduced to express Cas9 alone and in the cells in which Ern1 was targeted and stimulated these cells with thapsigargin to induce the UPR. Depletion of SKIV2L in the control cells resulted in an enhanced UPR-induced interferon response; however, this enhancement was significantly blunted in both lines of cells in which Ern1 was targeted (Fig. 3c) .
To formally establish a role for signaling via RLRs in the enhanced antiviral response in cells depleted of SKIV2L, we compared the induction of IFN-β expression in wild-type BMDMs with that of BMDMs deficient in the signaling adaptor MAVS, which lack RIG-Iand Mda5-induced production of type I interferons 39 . As expected, the interferon response to transfection of RIG-I ligand in wild-type cells, as well as the enhanced interferon response in cells depleted of SKIV2L, was entirely dependent on MAVS (Fig. 3d) . Similarly, the enhanced response to transfection of poly(I:C) in cells depleted of SKIV2L required MAVS, with the residual induction of interferon in MAVS-deficient cells probably mediated by the Toll-like receptor 3-TRIF pathway 20 (Fig. 3e) . Notably, we found that the induction of interferon during activation of the UPR in cells depleted of SKIV2L was also dependent on MAVS (Fig. 3f) . Together these data revealed SKIV2L as an important negative regulator of the RLR response to exogenous RNA ligands. Moreover, we identified the UPR as a source of endogenous RNA ligands that triggered an ectopic antiviral response in SKIV2L-deficient cells through an IRE-1α-and MAVS-dependent pathway.
SKIV2L-deficient humans have a type I interferon signature
We next explored a role for SKIV2L in regulating the type I interferon response in humans. Loss-of-function mutations in the human gene SKIV2L cause trichohepatoenteric syndrome (THES; OMIM entry number 222470) 40 . THES is an extremely rare disease characterized by growth retardation, facial dysmorphism, immunodeficiency, abnormalities of the liver and intestines and intractable diarrhea that npg requires parenteral nutrition 41 . These severe symptoms probably reflect the broad role of the cytosolic RNA exosome in maintaining RNA homeostasis in cells, as discussed below. In addition to the mutations in SKIV2L that cause THES, loss-of function mutations in TTC37, the gene that encodes the human ortholog of the yeast RNA exosome component SKI3, also cause the same disease 42, 43 . We obtained peripheral blood samples from two of the four living patients with THES who have biallelic SKIV2L mutations, as well as from three patients with THES who have TTC37 mutations and three control subjects heterozygous for THES-related mutations ( Table 1) . We confirmed complete loss of SKIV2L protein in extracts of a lymphoblastoid cell line derived from a patient with THES who has biallelic SKIV2L mutations (Fig. 4a) , which provided further support for the notion that these SKIV2L mutations indeed resulted in loss of function. We measured the relative abundance of six interferonstimulated genes (ISGs) (IFI27, IFI44L, IFIT1, ISG15, RSAD2 and SIGLEC1) by quantitative RT-PCR analysis of cDNA prepared from fresh blood samples. To establish the range of ISG expression in a wellcharacterized, interferon-mediated human autoimmune disorder and for comparison with our samples from patients with THES, we reproduced the published ISG profiles of blood samples from 82 patients with AGS and 29 healthy control subjects, and added three additional subjects heterozygous for THES-related mutations as controls 44 (Fig. 4b) . Notably, we found that both of the SKIV2L-deficient patients with THES had a type I interferon signature that was even more robust than the mean ISG scores of patients with AGS (Fig. 4b,c) . In contrast, we found no evidence of an interferon signature in the three patients with THES who have TTC37 mutations (Fig. 4b,c) . Our findings revealed a strong interferon signature in SKIV2Ldeficient patients with THES and established an important role for SKIV2L in negative regulation of the interferon-mediated antiviral response in humans. However, the lack of an interferon signature in TTC37-deficient patients with THES raised the possibility that SKIV2L and TTC37 contribute differently to this negative regulation.
Different roles for SKIV2L and TTC37 in RLR regulation
Given the presence of an interferon signature in SKIV2L-deficient patients with THES and its absence in TTC37-deficient patients with the same disease, we sought to determine whether SKIV2L has a unique function in the regulation of RLRs that is distinct from its role in the classic cytosolic RNA exosome that contains both SKIV2L and TTC37. We therefore established stable and efficient knockdown of TTC37 in primary mouse macrophages by lentivirus-delivered shRNA (Fig. 5a) . We found that depletion of SKIV2L markedly enhanced the interferon response to transfected RLR ligand. In contrast, macrophages depleted of TTC37 exhibited an interferon response similar to that of cells transduced with control shRNA with a scrambled sequence (Fig. 5b) . Similarly, knockdown of SKIV2L enhanced the interferon response to thapsigargin-induced activation of the UPR, but knockdown of TTC37 had no effect (Fig. 5c) . Together with the ISG data presented above from patients with THES ( Fig. 4) , these findings revealed a unique role for SKIV2L in the regulation of RLR responses distinct from its role in the SKIV2L-TTC37 cytosolic RNA exosome.
DISCUSSION
Our data have extended the paradigm of negative regulation of cell-intrinsic innate antiviral responses first described for the DNAsensing pathway 10 by identifying a key negative regulator of RLRs that detect RNA. We found that the cytosolic RNA exosome, defined by the presence of the RNA helicase SKIV2L, was important for limiting the activation of RLRs. We identified the UPR as a cellular stress response that generated endogenous RLR ligands, and we showed that cells undergoing a UPR triggered an aberrant interferon-mediated antiviral response if these endogenous RNAs were not metabolized. We found that humans with deficiency in SKIV2L had a strong type I interferon signature in their peripheral blood, indicative of a chronic antiviral response that may be relevant to human autoimmune disorders. Finally, we presented evidence obtained from human patients and mouse cells that the role of SKIV2L in the regulation of RLRs was independent of another exosome protein, TTC37. Together these findings reveal a previously unknown mechanism for the regulation of RLRs and emphasize the importance of intracellular metabolism of nucleic acids for preventing aberrant innate immune responses.
We found that cells depleted of SKIV2L had an enhanced IFN-β response to RLR ligands, but cells depleted of XRN1 did not. Perhaps more relevant to autoimmune disease, we identified the RNA-degradation products of IRE-1 generated during the UPR as a source of endogenous immunostimulatory RNAs that triggered a MAVSdependent interferon response in cells depleted of SKIV2L but not in wild-type cells. Notably, this finding revealed a mechanism by which a 'sterile' stress response might be misinterpreted as a viral infection if cells fail to metabolize the RNA-degradation products formed as a result of the stress. The UPR-activated RLR response in cells depleted of SKIV2L was robust and significant but was much less potent than the response to transfected triphosphate RNA. This probably reflected the number of RIG-I ligands introduced by transfection: 1 µg of transfected RIG-I ligand contains approximately 1 × 10 13 molecules, which would amount to ~10 × 10 6 molecules delivered per cell in our experimental system. In contrast, IRE-1-mediated cleavage of cellular mRNAs would generate far fewer endogenous RIG-I ligands. Moreover, it is also likely that 3′-cyclic-phosphate RNAs are less efficient activators of RLRs than are 5′-triphosphate RNAs 32, 34 . Despite the relatively weaker interferon response triggered by the UPR, we propose that such an interferon response in a chronic setting would be sufficient to drive substantial pathology.
Our findings suggest a potential previously unknown mechanism for the pathogenesis of certain autoimmune diseases that affect highly secretory cells that routinely undergo ER stress, including Sjögren's syndrome (which affects salivary and lacrimal glands) and type 1 diabetes (which affects insulin-secreting beta cells of the exocrine pancreas). We propose a simple model in which regular, episodic A r t i c l e s activation of the UPR would generate endogenous RIG-I ligands.
In people with deficiencies in their ability to metabolize these RNAs, this UPR would trigger a chronic, inappropriate antiviral response, leading to activation of the immune system and eventual destruction of the cells over time. Notably, our model emphasizes the role of the secretory cells themselves as active participants in the autoimmune process. By activating the cell-intrinsic antiviral response, these cells become the targets of an adaptive immune response, similar to the manner in which virus-infected cells are targeted for elimination by cytotoxic T cells.
We showed that human patients with deficiency in SKIV2L had a potent interferon signature in their peripheral blood cells and have thus provided evidence for the relevance of this regulatory mechanism to human disease. Our findings raise two questions. First, does this interferon signature contribute to the pathogenesis of THES? Given the lack of an interferon signature in TTC37-deficient patients with THES, we propose that most of the symptoms of this severe disease are the consequence of loss of the 'housekeeping' function of the cytosolic RNA exosome in the general turnover of RNA rather than the aberrant interferon response found only in SKIV2Ldeficient patients. Second, given the strong interferon signature, why do SKIV2L-deficient patients not develop autoimmunity? Notably, some patients with THES also exhibit immunodeficiency and require supplemental immunoglobulins 41 , which suggests an essential role for the RNA exosome in lymphocyte function. Indeed, we found that the survival of cells in which SKIV2L was knocked down was compromised after stimulation, which precluded several experiments we attempted, including infection with RNA viruses (data not shown). We suggest that defective lymphocyte function in patients with THES prevents overt autoimmune disease despite the potent interferon signature evident in their peripheral blood cells. However, the immunological aspects of THES have thus far been incompletely defined, in large part because of the extreme rarity of this disease and the severity of the other symptoms. It will be informative to further explore potential autoimmune phenotypes in THES and their different manifestations in patients with SKIV2L mutations and those with TTC37 mutations, given the findings presented above.
We have presented evidence that SKIV2L contributed to the regulation of RLRs but the other defined component of the cytosolic RNA exosome, TTC37, did not. The subcellular localization and RNA substrate specificity of the RNA exosome are determined by its associated cofactors, such that the exosome associated with SKIV2L and TTC37 is involved mainly in cytosolic RNA decay 14 . Moreover, the RNA exonucleases that also associate with the core exosome components can each mediate degradation of unique subsets of RNAs in cells 14 . We propose that the role for SKIV2L identified here is distinct from its involvement in the conventional cytosolic RNA exosome, and future studies should determine whether there are proteins that partner with SKIV2L that are uniquely involved in the regulation of RLRs. Such proteins may serve to target SKIV2L specifically to immunostimulatory RNAs.
In summary, we have identified a regulatory mechanism in which the metabolism of intracellular RNA ligands limited the activation of RLRs. We propose that deficient function of this regulatory mechanism would predispose a person to autoimmune diseases, particularly those that affect highly secretory cells. The identification of other components of this pathway might provide insight into the pathogenesis of certain interferon-associated autoimmune disorders.
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